Yale Study Finds Epilepsy Drug Lacosamide May Reverse Osteoarthritis via Targeted Hydrogel Delivery
Yale researchers discovered that lacosamide, an FDA-approved epilepsy medication, can simultaneously reduce pain and repair cartilage in osteoarthritis when delivered via a specialized hydrogel. The study, published in Bioactive Materials, identifies the Nav1.7 protein as a dual target for both pain signaling and cartilage degradation. By using a temperature-sensitive collagen hydrogel to keep the drug localized in the joint, the treatment outperformed daily oral doses in preclinical tests, offering a potential path to disease modification rather than just symptom management.
Key points
- Lacosamide, already approved for epilepsy, shows potential to reverse cartilage damage and reduce pain in osteoarthritis at low concentrations.
- The drug targets Nav1.7, a sodium channel found in both nerve cells and chondrocytes, which is overactive in osteoarthritis and drives tissue breakdown.
- A temperature-sensitive hydrogel made from Collagen II was developed to retain the drug in the joint for weeks, overcoming the rapid drainage of liquid injections.
- Preclinical studies showed that a single injection every four weeks was more effective at preventing cartilage loss than daily oral administration.
- The drug stimulates the release of HSP70 and midkine, proteins that support tissue repair and regulate inflammation, creating a favorable environment for cartilage maintenance.
Background
This development aligns with broader trends in drug repurposing and advanced delivery systems. While recent FDA approvals have faced scrutiny for relying on fewer trials and increased industry funding, this study leverages an existing approved drug to potentially accelerate clinical translation. The use of biomaterials to control drug release mirrors innovations seen in other therapeutic areas, aiming to improve efficacy and reduce systemic side effects compared to traditional oral medications.
How outlets are covering it
Both ScienceDaily and UA.NEWS report on the same study from Yale, led by Chuan-Ju Liu, published in Bioactive Materials. They agree on the core findings: lacosamide's dual action on pain and cartilage via Nav1.7 inhibition, and the superiority of the hydrogel delivery system over oral administration. ScienceDaily provides more detail on the biological mechanisms, specifically highlighting the role of HSP70 and midkine signaling proteins and the concept of an 'optimal dose' where effects are maximized. UA.NEWS offers a more concise summary, focusing on the practical implications of the hydrogel's temperature-sensitive properties and the potential for faster clinical trials due to lacosamide's existing approval status. Neither source presents conflicting data; rather, they emphasize different aspects of the same research, with ScienceDaily focusing on the molecular 'why' and UA.NEWS on the logistical 'how' of delivery and approval.
Why it matters
Osteoarthritis affects millions, with current treatments only masking pain without stopping structural joint damage. This research offers a potential shift toward disease-modifying therapies that can actually repair tissue. By repurposing an existing drug and using advanced delivery methods, the approach could bypass lengthy development timelines, potentially reducing the need for joint replacements and avoiding addictive opioids for pain management.
What to watch
The next step is moving from preclinical to clinical trials. Since lacosamide is already approved for human use, the regulatory pathway may be faster than for a new drug. Researchers will need to validate the efficacy and safety of the hydrogel delivery system in human patients, particularly for the knee, which is the most common site for osteoarthritis.
Want the full story? Read the original reporting
Read on ScienceDaily